Medicenna Therapeutics Corp. (MDNA.TO)
| Previous Close | 2.4200 |
| Open | 2.4200 |
| Bid | 2.2100 x N/A |
| Ask | 2.2400 x N/A |
| Day's Range | 2.2200 - 2.4200 |
| 52 Week Range | 0.2150 - 2.9800 |
| Volume | |
| Avg. Volume | 87,572 |
| Market Cap | 169.681M |
| Beta (5Y Monthly) | 1.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2300 |
| Earnings Date | Nov 12, 2024 - Nov 18, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.28 |
GlobeNewswireMedicenna to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
TORONTO and HOUSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that Dr. Fahar Merchant, President and CEO of Medicenna, will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference, taking place September 9-11, 2024 in New York, NY. Details on the fireside cha
- Baystreet
Stocks in play: Medicenna Therapeutics Corp.
Will present two abstracts, both as oral presentations, at the Promise of Interleukin-2 Therapy Conference, ...
- GlobeNewswire
Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference
TORONTO and HOUSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that the Company will present two abstracts, both as oral presentations, at the Promise of Interleukin-2 Therapy Conference, taking place at the Centre International de Conférences Sorbonne Université in Paris, France, from September 4-7, 2024. The Company will
